Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Cagrilintide vs CagriSema

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

CagriSema has stronger documented evidence (Phase 3) than Cagrilintide (Phase 2/3) while both occupy the amylin class. When clinical-evidence tier is the deciding factor, CagriSema is the safer pick. Cagrilintide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Cagrilintide

Phase 2/3

CagriSema

Phase 3

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: gi effects. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Cagrilintide CagriSema
Class Long-acting amylin analog Amylin + GLP-1 combination
Drug class Metabolic & Weight Metabolic & Weight
Mechanism Amylin receptor agonist; delays gastric emptying; enhances satiety Dual amylin + GLP-1 receptor agonism
Route SC injection SC injection
Half-life ~7 days ~7 days
Dosage (research) 0.3-4.5 mg SC weekly (often paired with semaglutide) 2.4 mg / 2.4 mg SC weekly
Evidence tier Phase 2/3 Phase 3
Research depth 139 indexed (PubMed 75 · CT 45 · EPMC 19) 113 indexed (PubMed 49 · CT 32 · EPMC 32)
Availability Investigational Investigational
Reported risks Nausea; GI effects; long-term data pending GI effects; Phase 3 REDEFINE mixed results

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Cagrilintide or CagriSema?

CagriSema has stronger documented evidence (Phase 3) than Cagrilintide (Phase 2/3) while both occupy the amylin class. When clinical-evidence tier is the deciding factor, CagriSema is the safer pick. Cagrilintide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Cagrilintide and CagriSema?

Cagrilintide is classed as Long-acting amylin analog; CagriSema is classed as Amylin + GLP-1 combination. Reported mechanism: Cagrilintide, Amylin receptor agonist; delays gastric emptying; enhances satiety; CagriSema, Dual amylin + GLP-1 receptor agonism. Reported half-life: Cagrilintide, ~7 days; CagriSema, ~7 days. Routes in published studies: Cagrilintide, SC injection; CagriSema, SC injection.

Which has stronger evidence, Cagrilintide or CagriSema?

CagriSema has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Cagrilintide is graded Phase 2/3, with 23 cited sources on its reference page and 139 indexed studies. CagriSema is graded Phase 3, with 25 cited sources on its reference page and 113 indexed studies.

Which is more accessible, Cagrilintide or CagriSema?

Neither Cagrilintide nor CagriSema is an FDA-approved drug. Catalog status: Cagrilintide, Investigational; CagriSema, Investigational.

Are Cagrilintide and CagriSema ever combined?

Cagrilintide and CagriSema appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…